Fluorine in Medicinal Chemistry
暂无分享,去创建一个
Martin Stahl | Manfred Kansy | Hans-Joachim Böhm | Stefanie Bendels | Bernd Kuhn | B. Kuhn | D. Banner | M. Stahl | M. Kansy | H. Böhm | K. Müller | Stefanie Bendels | U. Obst‐Sander | Ulrike Obst-Sander | David Banner | Klaus Müller
[1] H. Davis,et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. , 1997, The Journal of pharmacology and experimental therapeutics.
[2] H. Koga,et al. Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. , 1980, Journal of medicinal chemistry.
[3] P. Wolschann,et al. On the structure and torsional potential of trifluoromethoxybenzene: an ab initio and density functional study , 2003 .
[4] J. Clader. The discovery of ezetimibe: a view from outside the receptor. , 2004, Journal of medicinal chemistry.
[5] Xinjian Yan,et al. Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design. , 1996, Biochemistry.
[6] T. Maren,et al. A new class of carbonic anhydrase inhibitor. , 1993, The Journal of biological chemistry.
[7] H. Waterbeemd,et al. Pharmacokinetics and Metabolism in Drug Design: Smith: Pharmacokinetics , 2001 .
[8] W. E. Barnette. The synthesis and biology of fluorinated prostacyclins. , 1984, CRC critical reviews in biochemistry.
[9] R. Kurumbail,et al. Synthesis and X-ray crystal structures of substituted fluorobenzene and benzoquinone inhibitors of the tissue factor VIIa complex. , 2003, Bioorganic & medicinal chemistry letters.
[10] C. C. Kotoris,et al. Novel phosphate mimetics for the design of non-peptidyl inhibitors of protein tyrosine phosphatases. , 1998, Bioorganic & medicinal chemistry letters.
[11] Ericka Stricklin-Parker,et al. Ann , 2005 .
[12] Gordon M. Crippen,et al. Prediction of Physicochemical Parameters by Atomic Contributions , 1999, J. Chem. Inf. Comput. Sci..
[13] R. Kurumbail,et al. Design, synthesis, and crystal structure of selective 2-pyridone tissue factor VIIa inhibitors. , 2003, Journal of medicinal chemistry.
[14] F. Young. Biochemistry , 1955, The Indian Medical Gazette.
[15] J. Snyder,et al. Protonated 3-fluoropiperidines: an unusual fluoro directing effect and a test for quantitative theories of solvation , 1993 .
[16] B. Smart. Fluorine substituent effects (on bioactivity) , 2001 .
[17] R. S. Rogers,et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.
[18] D. Davey,et al. Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors. , 2003, Bioorganic & medicinal chemistry letters.
[19] A. Bondi. van der Waals Volumes and Radii , 1964 .
[20] A. Pike,et al. Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles. , 1999, Journal of medicinal chemistry.
[21] Paul Seiler,et al. A fluorine scan of thrombin inhibitors to map the fluorophilicity/fluorophobicity of an enzyme active site: evidence for C-F...C=O interactions. , 2003, Angewandte Chemie.
[22] B. Sweatman,et al. Urinary metabolites of a novel quinoxaline non-nucleoside reverse transcriptase inhibitor in rabbit, mouse and human: identification of fluorine NIH shift metabolites using NMR and tandem MS , 2000, Xenobiotica; the fate of foreign compounds in biological systems.
[23] D. Christianson,et al. Fluoroaromatic-fluoroaromatic interactions between inhibitors bound in the crystal lattice of human carbonic anhydrase II. , 2001, Journal of the American Chemical Society.
[24] A. Beatty,et al. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors. , 1999, Journal of medicinal chemistry.
[25] N. Kitteringham,et al. Metabolism of fluorine-containing drugs. , 2001, Annual review of pharmacology and toxicology.
[26] J. Domagala,et al. New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. , 1986, Journal of medicinal chemistry.
[27] Chu-Young Kim,et al. Contribution of Fluorine to Protein−Ligand Affinity in the Binding of Fluoroaromatic Inhibitors to Carbonic Anhydrase II , 2000 .
[28] S. Chakravarty. Chapter 18. Inhibitors of p38α MAP kinase , 2002 .
[29] R. Kurumbail,et al. Synthesis and crystal structures of substituted benzenes and benzoquinones as tissue factor VIIa inhibitors. , 2003, Journal of medicinal chemistry.
[30] C. Swain,et al. Chapter 6. Progress in the Development of Neurokinin Antagonists , 1999 .
[31] C. Supuran,et al. Carbonic Anhydrase Inhibitors: X-ray Crystallographic Structure of the Adduct of Human Isozyme II with the Perfluorobenzoyl Analogue of Methazolamide. Implications for the Drug Design of Fluorinated Inhibitors , 2003, Journal of enzyme inhibition and medicinal chemistry.
[32] J. Vervoort,et al. Occurrence of the NIH shift upon the cytochrome P450-catalyzed in vivo and in vitro aromatic ring hydroxylation of fluorobenzenes. , 1998, Chemical research in toxicology.
[33] J. Boehm,et al. 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. , 1996, Journal of medicinal chemistry.
[34] M. Bols,et al. Stereoelectronic substituent effects in polyhydroxylated piperidines and hexahydropyridazines. , 2002, Chemistry.
[35] J. Doyon,et al. The pattern of fluorine substitution affects binding affinity in a small library of fluoroaromatic inhibitors for carbonic anhydrase. , 1999, Organic letters.
[36] H. Rzepa,et al. Some influences of fluorine in bioorganic chemistry , 1997 .
[37] Robin Taylor,et al. Organic Fluorine Hardly Ever Accepts Hydrogen Bonds , 1997 .
[38] B. Witherbee,et al. Novel heteroaryl replacements of aromatic 3-tetrafluoroethoxy substituents in trifluoro-3-(tertiaryamino)-2-propanols as potent inhibitors of cholesteryl ester transfer protein. , 2001, Bioorganic & medicinal chemistry letters.